Last updated: 2026-10-18 22:17:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Benitec Biopharma Inc. (BNTC) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $8.08, with a market capitalization of $282.90M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8.06 to $16.76. This page covers its latest market performance, valuation, price trends and company information.
$282.90M | |
$8.47 | |
$295.62 | |
$1.86 | |
$8.46 | |
139.26K | |
163.47K | |
-- | |
$16.76 | |
$8.06 | |
-- | |
-- |
Benitec Biopharma Inc. (BNTC) last closed at $8.46 as of 2026-10-16 19:59:49, unchanged from the previous close of $8.46.
During the latest regular trading session, BNTC traded between $1.86 and $295.62, with a volume of 139.26K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Benitec Biopharma Inc. (BNTC) moved from $8.75 to $8.08, representing a decline of 7.61% ($0.67).
The stock traded between $8.06 and $9.25 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 162.16 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.3%
BNTC is currently trading at $8.08, placing it 0.3% of the way from its 52-week low of $8.06 to its 52-week high of $16.76. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 24 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Benitec Biopharma Inc. (BNTC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.